An Oral Selective Alpha-1A Adrenergic Receptor Agonist Prevents Doxorubicin Cardiotoxicity

Autor: Ju Youn Beak, PhD, Wei Huang, Joel S. Parker, PhD, Sean T. Hicks, BS, Cam Patterson, MD, Paul C. Simpson, MD, Anqi Ma, PhD, Jian Jin, PhD, Brian C. Jensen, MD

Publikováno v: JACC: Basic to Translational Science, Vol 2, Iss 1, Pp 39-53 (2017)

Summary: Alpha-1 adrenergic receptors (α1-ARs) play adaptive and protective roles in the heart. Dabuzalgron is an oral selective α1A-AR agonist that was well tolerated in multiple clinical trials of treatment for urinary incontinence, but has

Externí odkaz: https://doaj.org/article/163241d636d34380ab2fd19363f521ab

An Oral Selective Alpha-1A Adrenergic Receptor Agonist Prevents Doxorubicin Cardiotoxicity

Autor: Jian Jin, Brian C. Jensen, Paul C. Simpson, Ju Youn Beak, Cam Patterson, BS Sean T. Hicks, Anqi Ma, Joel S. Parker, Wei Huang

Publikováno v: JACC. Basic to translational science, vol 2, iss 1
Beak, J; Huang, W; Parker, JS; Hicks, ST; Patterson, C; Simpson, PC; et al.(2017). An Oral Selective Alpha-1A Adrenergic Receptor Agonist Prevents Doxorubicin Cardiotoxicity.. JACC. Basic to translational science, 2(1), 39-53. doi: 10.1016/j.jacbts.2016.10.006. UCSF: Retrieved from: http://www.escholarship.org/uc/item/11z122s7
JACC: Basic to Translational Science, Vol 2, Iss 1, Pp 39-53 (2017)

Summary: Alpha-1 adrenergic receptors (α1-ARs) play adaptive and protective roles in the heart. Dabuzalgron is an oral selective α1A-AR agonist that was well tolerated in multiple clinical trials of treatment for urinary incontinence, but has

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63eddc7a9d6873a0911ea187e47443ab
https://doi.org/10.1016/j.jacbts.2016.10.006

Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition

Autor: Traci L. Parry, Noah Sciaky, Jon S. Zawistowski, Ju Youn Beak, Xin Chen, Steven P. Angus, Sean T Hicks, Wei Huang, Monte S. Willis, Brian C. Jensen, Timothy J. Stuhlmiller, Gary L. Johnson

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Background Most novel cancer therapeutics target kinases that are essential to tumor survival. Some of these kinase inhibitors are associated with cardiotoxicity, whereas others appear to be cardiosafe. The basis for this distinction is unclear, as a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0a2070a0da24cd1e09499477683b50c
https://doi.org/10.1161/jaha.117.006635